Needham analyst Mike Matson downgraded ShockWave Medical (SWAV) to Hold from Buy following the recently announced agreement for an acquisition of the company by Johnson & Johnson (JNJ). The acquisition will complement JNJ’s other cardiovascular businesses, including Abiomed and Laminar, the analyst tells investors in a research note. The offer also values ShockWave Medical fairly, and the firm does not expect any antitrust issues due to a lack of product overlap, Needham states, adding that a higher bid for the company is unlikely.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SWAV:
- ShockWave Medical downgraded to Market Perform from Outperform at Leerink
- ShockWave Medical downgraded to Hold from Buy at Canaccord
- ShockWave Medical downgraded to Neutral from Overweight at Piper Sandler
- Krispy Kreme upgraded, Altice USA downgraded: Wall Street’s top analyst calls
- M&A News: Johnson & Johnson (NYSE:JNJ) Enters Into $13.1B Shockwave Medical Deal